Table 1.

Baseline patient characteristics and therapeutic regimens used

Characteristic	Total no. of patients (n = 46)	Frequency, %
Sex
Female	18	39
Male	28	61
Age, years
< 55	14	30
55–65	12	26
> 65	20	44
Metastatic site
1	15	33
2	12	26
> 2	19	41
Initial treatment
Bevacizumab‐mFOLFOX6	22	48
Bevacizumab‐FOLFIRI	13	28
Bevacizumab‐CapOX	2	4
Bevacizumab‐CapIRI	9	20
Maintenance treatment
Bevacizumab‐mFOLFOX6	4	9
Bevacizumab‐FOLFIRI	5	10
Bevacizumab‐CapIRI	9	20
Bevacizumab‐De Gramont	11	24
Bevacizumab‐Capecitabine	3	7
Bevacizumab monotherapy	14	30
Response to treatment
Complete response	1	2
Partial response	16	35
Stable disease	25	54
Disease progression	4	9

Bevacizumab‐mFOLFOX6 (bevacizumab 5 mg/kg, oxaliplatin 85 mg/m², folinic acid 400 mg/m², fluorouracil 400 mg/m² bolus, fluorouracil 2,400 mg/m² over 46 hours every 2 weeks), Bevacizumab‐FOLFIRI (bevacizumab 5 mg/kg, irinotecan 180 mg/m², folinic acid 400 mg/m², fluorouracil 400 mg/m² bolus, fluorouracil 2,400 mg/m² over 46 hours every 2 weeks), Bevacizumab‐CapOX (bevacizumab 7.5 mg/kg on d1, oxaliplatin 130 mg/m² on d1, capecitabine 1,000 mg/m² per 12 hours d1–14 every 3 weeks), Bevacizumab‐CapIRI (bevacizumab 7.5 mg/kg on d1, irenotecan 250 mg/m² on d1, capecitabine 1,000 mg/m² per 12 hours d1–14 every 3 weeks), Bevacizumab‐De Gramont (bevacizumab 5 mg/kg, folinic acid 200 mg/m² on d1,2, fluorouracil 400 mg/m² bolus on d1,2, fluorouracil 2,400 mg/m² over 22 hours on d1,2 every 2 weeks), Bevacizumab‐Capecitabine (bevacizumab 7.5 mg/kg on d1, capecitabine 1,000 mg/m² per 12 hours d1–14 every 3 weeks), Bevacizumab monotherapy (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks).